Medicinal Psychedelics Are About to Take Wall Street By Surprise

We've Got the Trinity Engaged with Clearmind Medicine, Inc. ($CMND), Our Next Micro-Float Gem

Medicinal psychedelics refer to the use of psychedelic drugs as part of the treatment of mental health conditions. Notable for having a low risk of physical dependence and abuse, medicinal psychedelics could be a profitable investment opportunity as research and a broader market for these substances continue to emerge.





What You should know

Development of Biotech

Biotechnology and pharmaceutical companies incur astronomical costs as part of the development of new products and processes. Extensive research time is a key reason for these costs although recreating the products and processes of competitors is relatively inexpensive (1).

By investing into patents on developments and research, biotechnology and pharmaceutical businesses can reduce the risk of copied products entering the marketplace. Yet not every biotechnology or pharmaceutical company sees a product through from design to manufacture. For smaller biotech and pharma firms, licensing their patented innovations to larger firms with the resources capable of producing them and taking them to market often makes more sense.

The success of these smaller companies depends on whether they can adequately convey the benefits of their intellectual property strategies to market participants.

Biotech and Pharmaceutical companies are responsible for some of the most innovative developments in the world.

These products are the technological advances that make life better (2).

Clearmind Medicine develops breakthrough treatments for binge behavior and mental health, including alcohol use disorder, binge eating, and depression.

The novel treatment candidates developed by Clearmind are backed by rigorous science and well-defined intellectual property. This video offers a brief look at the science behind MEAI and its related patents (4).

Clearmind Medicine Inc.

What are Medicinal Psychedelics?

Medicinal psychedelics refer to the use of psychedelic drugs as part of the treatment of mental health conditions. Notable for having a low risk of physical dependence and abuse, medicinal psychedelics could be a profitable investment opportunity as research and a broader market for these substances grow.


MEAI molecule
Over 57 million Americans report four or more episodes of heavy drinking per month with an average of seven drinks per episode (3).
MEAI exerts a euphoric alcohol-like experience and a reduced desire to consume alcoholic beverages with potential to change the lives of millions who struggle to drink in moderation.

Chart Analysis


Current Price: $3.56

1st Target: $4.09 (+14.89%)

2nd Target: $5.85 (+42.98%)

3rd Target: $5.85 (+64.33%)

Support At $3.36

Some observations:

  • RSI holding Above 50 on the daily time frame
  • MACD curling to the upside
  • Higher high validated, higher low is currently forming
  • Recent trendline break led into run-up

Exploring the Therapeutic Potential and Investment Opportunities of Medicinal Psychedelics

Medicinal psychedelics, also known as psychedelic drugs or entheogens, have shown promising potential in the treatment of a variety of mental health conditions, including depression, anxiety, post-traumatic stress disorder (PTSD), addiction, and even some physical conditions like chronic pain and migraines.

These substances have been used for centuries in traditional medicinal and spiritual practices, and have recently gained renewed interest for their potential therapeutic uses.

The Benefits of Medicinal Psychedelics

Psychedelics facilitate deep self-exploration and introspection, which can lead to profound personal insights and growth. They've been shown to stimulate neuroplasticity (7), which can lead to long-lasting improvements in cognition and behavior. These characteristics are what led to psychedelics being explored as a potential treatment for mental health conditions, especially for individuals who are resistant to traditional therapies.

Another benefit is their low risk of physical dependence and abuse. Unlike many traditional psychiatric medications, research has insofar not shown psychedelic drugs to be physically addictive. In fact, the likelihood of negative side effects becomes nearly zero when used in a therapeutic setting.

Microscope with flasks

SciSparc and Clearmind Reveal Three Unique Combinations of Future Psychedelic-Based Compounds

February 22, 2023

Tel Aviv, Israel, Feb. 22, 2023 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that as part of its ongoing collaboration with Clearmind Medicine Inc...

In Other News

Clearmind CEO Issues Letter to Shareholders

Clearmind Medicine CEO, Dr. Adi Zuloff-Shani, issues a letter to the company’s shareholders.

Ex-Red Bull Exec to Oversee Development of Groundbreaking Alcoholism Treatment

Clearmind Medicine announces the appointment of seasoned regulatory executive Nicholas Kadysh, previously an executive for Red Bull, as special advisor for the development of MEAI as an alcohol substitute.

Clearmind Closes US$7.5M Public Offering

Clearmind Medicine announces the closing of its underwritten public offering of 1,153,847 common shares at a price to the public of US$6.50 per share (CAD$8.65), for aggregate gross proceeds of US$7.5 million.

Antenna tower receiving a wireless transmission

The Board of

Clearmind Medicine

A company is only as strong as its team. Fortunately, Clearmind Medicine has incredible talent at the helm.

Looking for even more information?


Stock Research Today is a project of Virtus Media Group LLC and intended solely for entertainment and informational purposes. Consult your financial, investment and tax advisors to determine what financial and tax strategies may be right for you. Investor protection and other important information is available at This website / media webpage is owned, operated and edited by Virtus Media LLC. Any wording found on this website / media webpage or disclaimer referencing “I” or “we” or “our” or “Virtus Media” refers to Virtus Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage .We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. Virtus Media business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our websites, email, sms, push notifications, influencers, social media postings, ticker tags, press releases, online interviews, podcasts, videos, audio ads, banner ads, native ads, responsive ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors.

We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company's website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, Virtus Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers' works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer's communications regarding the profiled company(s). You should assume all information in all of our communications in incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice. Compensation: Pursuant to an agreement between Virtus Media LLC and Lifewater Media, Virtus Media LLC has been hired for a period beginning on 12/19/22 and ending 12/23/22 to publicly disseminate information about (NASDAQ: CMND) via digital communications. We have been paid fifteen thousand dollars USD via ACH Bank Transfer. Pursuant to an agreement between Virtus Media LLC and Lifewater Media LLC, Virtus Media has been hired for a period beginning on 2023-03-16 and ending after 2023-03-18 to publicly disseminate information about NASDAQ: CMND. We have been paid twelve thousand five hundred USD via ACH Bank Transfer.